PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 干扰素是复发缓解型多发性硬化症(RRMS)最常用的一线治疗药物。一些研究表明，在相当大比例的MS患者中，使用干扰素-β会产生中和抗体(NAB)，这被认为会降低干扰素-β的生物利用度，降低其治疗效果。这项研究将检验在治疗方案中加入类固醇(甲基强的松龙；MP)是否会阻止或减少抗体的发展，从而提高REBIF的有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Interferon-beta (IFN-beta; e.g., Rebif) is the most frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Several studies have shown that the use of IFN-beta produces neutralizing antibodies (NAbs) in a significant proportion of MS patients, which are thought to decrease the bio-availability of IFN-beta and reduce its therapeutic effects. This study will examine whether the addition of steroids (methylprednisolone; MP) to the treatment regime will prevent or decrease the development of antibodies, thus improving the effectiveness of Rebif.